Zhitong Finance App News, Shengnuo Biotech (688117.SH) announced that Chengdu Shengnuo Biopharmaceutical Co., Ltd. (hereinafter referred to as “Shengnuo Pharmaceutical”), a wholly-owned subsidiary of the company, underwent on-site inspections by the US Food and Drug Administration (“FDA”) inspection team from August 20, 2026 to August 22, 2026, and August 27, 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.